Kansai Hepatobiliary Oncology Group

Quick facts

Phase 2 pipeline

• Interferon Alfa、Fluorouracil · Oncology
  Interferon alfa binds to interferon receptors on the surface of cells, leading to the activation of JAK-STAT signaling pathways which enhance antiviral and antiproliferative responses; Fluorouracil inhibits thymidylate synthase, disrupting DNA synthesis and repair in rapidly dividing cells.

Phase 1 pipeline

• S-1, Gemcitabine, Cisplatin

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Kansai Hepatobiliary Oncology Group portfolio CI brief
• Kansai Hepatobiliary Oncology Group pipeline updates RSS